Patent intelligence · US
US 8178114
Patch device for a fragrance and method of using the patch device
Patch device for a fragrance and method of using the patch device
Patent details — US 8178114
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 15, 2012
- Expiration
- May 10, 2032
- Applicant
- Sentiv ApS
- Claims
- 17
- CPC classes
- A61K, A61K2800/56, A61K8/0208
Quick answer
US 8178114 (Patch device for a fragrance and method of using the patch device) is held by Sentiv ApS. Status: granted. Granted May 15, 2012. Expires May 10, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Sentiv ApS
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K2800/56, A61K8/0208
More from Sentiv ApS
Related pharmaceutical patents in our USPTO index.
-
US 12419895
Methods for treating subjects with Prader-Willi syndrome
granted -
US 12350258
Compositions and methods for treatment of skin-related diseases and promoting dermatological health
granted -
US 12343348
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12343381
Dosage regimen for pegylated interferon
granted -
US 12178823
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12109216
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12005081
Chimeric receptors and methods of use thereof
granted -
US 11884656
Pyrrole derivatives as PLK1 inhibitors
granted
Frequently asked questions
What is US patent 8178114?
US 8178114 (Patch device for a fragrance and method of using the patch device) is held by Sentiv ApS. Status: granted. Granted May 15, 2012. Expires May 10, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8178114?
Sentiv ApS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 95 pharmaceutical patents for this assignee.
When does US 8178114 expire?
Our index shows an expiration date of May 10, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.